HBV Reactivation Screening: Identifies the risk tier for patients starting immunosuppressive therapy to guide pre-emptive antiviral use.
High Risk (>10%)
Rituximab (Anti-CD20), Bone Marrow Transplant, or Anthracyclines (HBsAg+).
Moderate Risk (1–10%)
TNFi (Infliximab), High-dose Steroids (>20mg/d, >4wks), or HBsAg-/anti-HBc+ on Anthracyclines.
Low Risk (<1%)
Standard Methotrexate, Azathioprine, or short-term low-dose Steroids.